• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

ReCor Medical

ReCor Medical completes enrollment in renal denervation trial for treating hypertension

March 29, 2022 By Sean Whooley

ReCor Medical announced today that it completed enrollment in its Radiance-II pivotal trial of the Paradise ultrasound renal denervation (uRDN) system. The Radiance-II trial of the Paradise uRDN system will evaluate the platform in the treatment of uncontrolled hypertension in patients on zero-to-two antihypertensive oral medications. ReCor Medical designed its Paradise platform as a device-based, […]

Filed Under: Blood Management, Catheters, Clinical Trials, Featured Tagged With: ReCor Medical

ReCor Medical’s ultrasound renal denervation system launches in Europe

October 6, 2021 By Sean Whooley

ReCor Medical announced today that it launched its Paradise ultrasound renal denervation system in Germany. Palo Alto, California-based ReCor said in a news release that it made its Paradise system available for treating uncontrolled hypertension, with Heart Center Leipzig and Saarland University Hospital (Homburg/Saar). The company designed its Paradise platform as a device-based, minimally invasive […]

Filed Under: Blood Management, Business/Financial News, Cardiovascular, Catheters, Clinical Trials, Featured, Neurological, Neuromodulation/Neurostimulation Tagged With: ReCor Medical

Is renal denervation back as a high blood pressure treatment?

May 18, 2021 By Chris Newmarker

Medtronic (NYSE:MDT) today reported clinically significant and sustained blood pressure reduction among nearly 3,000 people with uncontrolled hypertension treated with the company’s Symplicity renal denervation system. The study results, reported today out of the 2021 EuroPCR Annual Meeting, come the same week as ReCor Medical touted its own positive renal denervation study at the American […]

Filed Under: Cardiovascular, Featured, Neurological, Research & Development Tagged With: Medtronic, ReCor Medical, renal denervation

5 of the latest cardiac tech insights out of ACC.21

May 17, 2021 By Nancy Crotti

The American College of Cardiology’s 70th Annual Scientific Session has produced some positive news about some controversial cardiac tech. Drug-coated stents, which a 2018 study linked to late-stage death, were shown to be non-inferior to non-drug-coated stents in patients with peripheral arterial disease. And a new study of renal denervation that used a different methodology […]

Filed Under: Cardiac Implants, Cardiovascular, Catheters, Clinical Trials, Drug-Device Combinations, Drug-Eluting Stents, Featured, Implants, Replacement Heart Valves, Stents, Vascular Tagged With: American College of Cardiology, atricure, Beth Israel Deaconess Medical Center, Boston Scientific, Edwards Lifesciences, Medtronic, ReCor Medical

ReCor Medical has positive renal denervation study news

May 17, 2021 By Chris Newmarker

ReCor Medical‘s renal denervation significantly reduced blood pressure among people with drug-resistant hypertension, according to a new study reported at the American College of Cardiology’s 70th Annual Scientific Session. The study news, announced yesterday, could suggest a turnaround in fortunes for renal denervation technology. One considered the next big thing in the medical device industry, […]

Filed Under: Cardiovascular, Catheters, Featured, Neuromodulation/Neurostimulation Tagged With: ACC 2021, Medtronic, ReCor Medical, renal denervation

The top 10 catheter innovations of 2020

December 28, 2020 By Danielle Kirsh

As the COVID-19 pandemic took over the world in 2020, medical device companies continued to showcase new catheter innovations. Throughout 2020, we saw FDA clearances, approvals and product launches for a variety of catheter-based technologies, including renal denervation systems, heart failure treatment catheters, mechanical thrombectomy systems and more. The list includes some medtech giants like […]

Filed Under: Cardiovascular, Catheters, Featured, Stents Tagged With: Boston Scientific, Johnson & Johnson, Penumbra, Philips, precardia, ReCor Medical, Revamp Medical, RIST Neurovascular, SoniVie

ReCor Medical gains FDA breakthrough nod for renal denervation system

December 11, 2020 By Danielle Kirsh

ReCor Medical this week announced that its Paradise ultrasound renal denervation system won FDA breakthrough device designation following positive results in a study. The Palo Alto, Calif.-based company’s Paradise system is an investigational device that is designed to treat hypertensive patients who may not be sufficiently responsive to or are tolerant of anti-hypertensive medical therapy. […]

Filed Under: Cardiovascular, Catheters Tagged With: FDA, ReCor Medical

ACC 2019 Roundup – ReCor touts six-month Paradise renal denervation study results

March 19, 2019 By Fink Densford

ReCor Medical this week released “on-medication” results from the RADIANCE-HTN-SOLO clinical trial of its Paradise renal denervation system intended to treat uncontrolled hypertension, touting medication and blood pressure reductions at six months. Results from the trial was presented at the American College of Cardiology’s 68th Annual Scientific Sessions in New Orleans and were simultaneously published […]

Filed Under: Cardiovascular, Clinical Trials, Featured, Patient Monitoring, Structural Heart Tagged With: ReCor Medical

Otsuka to acquire renal denervation firm ReCor Medical

July 10, 2018 By Brad Perriello

Otsuka Holdings (TYO:4578) said today that it plans to acquire the remaining stake it doesn’t already own in ReCor Medical and the renal denervation device it’s developing to treat hypertension. Tokyo-based Otsuka led ReCor’s $15 million Series D in April 2015 to back Palo Alto, Calif.- and Amsterdam-based ReCor’s Radiance-HTN study, which will test its Paradise system in patients […]

Filed Under: Mergers & Acquisitions, Ultrasound, Wall Street Beat Tagged With: Hypertension, Otsuka Holdings, ReCor Medical, Renal

FDA approves ReCor Medical’s pivotal ultrasound denervation study

July 5, 2018 By Sarah Faulkner

ReCor Medical said this week that the FDA approved a new pivotal study of the company’s Paradise ultrasound denervation system for the treatment of hypertension. The Palo Alto, Calif.-based company reported that its trial, Radiance-II, will be a randomized, sham-controlled study in patients with moderate hypertension. The study is designed to demonstrate the Paradise system’s […]

Filed Under: Blood Management, Cardiovascular, Clinical Trials, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: ReCor Medical

EuroPCR 2018 Roundup: Medtronic touts BP reductions, no major adverse events in renal denervation trial

May 23, 2018 By Fink Densford

Medtronic (NYSE:MDT) today released six-month results from a trial of its Symplicity Spyral renal denervation system exploring its use treating hypertensive patients who are already taking anti-hypertension medications, touting significant reductions in blood pressure and no major adverse safety events. Results were presented at the 2018 EuroPCR annual meeting in Paris and were published in The […]

Pages: Page 1 Page 2 Page 3

Filed Under: Blood Management, Cardiac Implants, Cardiovascular, Clinical Trials Tagged With: Abbott, Medtronic, ReCor Medical

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS